In summary, existing studies support the feasibility of clinical trials and treatment strategies targeting SIRT3 and SIRT6, providing a theoretical basis for the further development of Sirtuin-targeted therapies for pulmonary fibrosis. This evidence concerns the gene SIRT6 and pulmonary fibrosis.